Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Datopotamab Deruxtecan with Osimertinib for EGFR-Mutated NSCLC
The combination of osimertinib and datopotamab deruxtecan showed clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. The 6 mg/kg
New Indication: Axitinib for Advanced Neuroendocrine Tumors
Axitinib combined with octreotide LAR in patients with advanced progressive extrapancreatic neuroendocrine tumors showed an increase in progression-free survival assessed by blinde
New Protocol: Neoadjuvant Docetaxel with Trastuzumab and Pertuzumab in HER2 + Breast Cancer
In the neoCARHP trial, the THP regimen was found to be noninferior to TCbHP in terms of pathologic complete response rates but had fewer grade 3 or higher adverse events. The omiss
New Reference: Toripalimab with Chemotherapy for Advanced Esophageal SCC
In the JUPITER-06 trial, toripalimab combined with chemotherapy significantly improved overall and progression-free survival in patients with advanced esophageal squamous cell carc
New Reference: Temozolomide for Anaplastic Glioma
The CATNON trial demonstrated a survival benefit with adjuvant temozolomide in patients with IDH-mutated astrocytoma compared to radiotherapy alone. Concurrent temozolomide did not
New Protocol: Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Metastatic Breast Cancer
ASCENT-04 phase 3 trial showed that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared to chemotherapy plus pembrolizumab in patient
New Protocol: Lenvatinib with Bevacizumab for Gynecological Clear Cell Carcinoma
In this phase 2 trial of pembrolizumab plus lenvatinib in patients with recurrent gynaecological clear cell carcinoma, the combination of lenvatinib and pembrolizumab showed a 40%
New Protocol: Letrozole and Palbociclib with Trastuzumab and Pertuzumab for Neoadjuvant Triple-Positive Breast Cancer
The TOUCH trial showed that palbociclib and letrozole combined with dual anti-HER2 therapy achieved similar pCR rates to paclitaxel in HR-positive/HER2-positive early breast cancer
New Reference: Palbociclib Addition to Maintenance Therapy in Triple-Positive Breast Cancer
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improved progression-free survival in patients with hormone-receptor-positive, HER2-posit
